FDA Innovation And Integrity Will Be Goodman's Role Under Reorganization
FDA's Office of Chief Scientist will lose some specific responsibilities but gain a broader mission under a reorganization proposed by Commissioner Margaret Hamburg
You may also be interested in...
Gaining the expertise and infrastructure needed to assess products of the future - such as biosimilars and those based on stem cells and nanotechnology - is the goal of a $25 million scientific modernization effort proposed in the fiscal 2011 FDA budget
BIO executive VP John Taylor returns to the agency as special counselor while FDA also fills another key liaison slot.
The FDA Commissioner says the realignment of four deputy-level offices in the Office of the Commissioner will streamline "common activities" and strengthen science and food safety